Smith & Nephew Sets Sterling Rate for 2025 Final Dividend Ahead of May 27 Payout

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An update from Smith & Nephew Snats ( (SNN) ) is now available. Smith & Nephew plc has confirmed the sterling equivalent of its previously announced final dividend for the year ended 31 December 2025, with a payout of 24.1 US cents per ordinary share to be made on 27 May 2026 to shareholders on the register as of 27 March 2026. UK-registered shareholders and those who have elected to receive their dividends in sterling will receive 17.78 pence per share, providing clarity on the cash return and reinforcing the company’s ongoing capital distribution to investors. The announcement, filed on 12 May 2026, formalizes the currency conversion for the final dividend and underscores Smith & Nephew’s adherence to U.S. securities reporting requirements as a foreign private issuer. This confirmation helps income-focused shareholders plan their cash flows and signals the company’s commitment to maintaining shareholder returns following its 2025 financial year performance. The most recent analyst rating on (SNN) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page. Spark’s Take on SNN Stock According to Spark, TipRanks’ AI Analyst, SNN is a Outperform. The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds. To see Spark’s full report on SNN stock, click here. More about Smith & Nephew Snats Smith & Nephew plc is a UK-based medical technology company listed in the U.S. as a foreign private issuer, supplying advanced devices and solutions for orthopaedics, sports medicine and wound care. The group operates globally and reports under the Securities Exchange Act, reflecting its role as an international healthcare manufacturer serving hospitals and clinicians worldwide. Average Trading Volume: 1,009,910 Technical Sentiment Signal: Sell Current Market Cap: $12.68B For an in-depth examination of SNN stock, go to TipRanks’ Overview page.